Medical Device Single Audit Program Gains Momentum

The GMP Letter
A A
Companies most likely to benefit from the Medical Device Single Audit Program will include those selling products in Canada, along with manufacturers of finished medical devices and high-risk devices, said MDSAP expert Brian Ludovico, in an FDAnews webinar.

To View This Article:

Login

Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00